Table 1.

Baseline characteristics

		Treatment as usual (n=245)	Cognitive behavioural therapy plus treatment as usual (n=242)
Age, years		42·8 (10·4)	42·2 (10·7)
Sex
	Male	173 (71%)	176 (73%)
	Female	72 (29%)	66 (27%)
Ethnicity
	White	222 (91%)	222 (92%)
	Asian	4 (2%)	9 (4%)
	Black	3 (1%)	5 (2%)
	Mixed	12 (5%)	4 (2%)
	Other	3 (1%)	2 (1%)
	Refused to answer	1 (<1%)	..
Employment
	Paid, full or part time	10 (4%)	10 (4%)
	Voluntary	16 (7%)	14 (6%)
	Education or training	5 (2%)	9 (4%)
	Other unpaid activity	8 (3%)	6 (3%)
	Unemployed	204 (83%)	203 (84%)
	Missing	2 (1%)	..
Residential status
	Inpatient	16 (7%)	17 (7%)
	Rehabilitation ward	8 (3%)	13 (5%)
	Supported accommodation	45 (18%)	39 (16%)
	Independent living	174 (71%)	172 (71%)
	Missing	2 (1%)	1 (<1%)
Full-time education, years		12 (11–14); 229	12 (11–14); 223
Untreated psychosis, months		18 (2–48); 203	8 (1–24); 195
Illness, months		240 (144–300); 231	216 (132–300); 227
Diagnosis at baseline
	Schizophrenia	218 (89%)	209 (86%)
	Schizoaffective	20 (8%)	28 (12%)
	Delusional disorder	5 (2%)	2 (1%)
	Unspecified psychosis*	1 (<1%)	2 (1%)
	Missing	1 (<1%)	1 (<1%)
Prescribed clozapine		221 (90%)	223 (92%)
Time on clozapine, months		60 (24–120); 216	60 (24–120); 218
Clozapine dose, mg		400 (300–500); 221	400 (300–525); 221
Discontinued clozapine		24 (10%)	19 (8%)
Time discontinued, months		13 (3–20); 24	9 (5–13); 19
Reasons for discontinuing clozapine
	Side-effects	23 (96%)	16 (84%)
	Lack of efficacy	1 (4%)	3 (16%)
Taking other antipsychotic medication
	None	142 (58%)	136 (56%)
	One	95 (39%)	99 (41%)
	Two	7 (3%)	7 (3%)
	Three	1 (<1%)	..
Other medication
	Antidepressants	129 (53%)	113 (47%)
	Other mental health medication	35 (14%)	52 (22%)
	Benzodiazepines	30 (12%)	27 (11%)
	Medication for antipsychotic side-effects	24 (10%)	27 (11%)

Data are mean (SD), n (%), or median (IQR); N.

^*Not due to a substance or known physiological condition.